This report provides a comprehensive analysis of the global genomic cancer testing market, projecting significant growth through 2032. It examines key technologies such as Next-Generation Sequencing and digital PCR, while covering diverse segments including tissue and liquid biopsies. Driven by rising cancer burdens and the expansion of precision medicine, the industry is shifting toward integrated disease management. The study evaluates market dynamics, competitive landscapes, and regional trends across the Americas, APAC, and Europe to identify emerging opportunities.

Market Overview

The global Genomic Cancer Testing market is projected to grow from US$ 16455 million in 2025 to US$ 30739 million in 2032, representing a compound annual growth rate (CAGR) of 9.4% from 2026 to 2032.

Definition

Genomic Cancer Testing refers to a class of molecular diagnostic technologies and services that analyze DNA, RNA, and other molecular-level genetic information in a patient's tumor tissue or body fluids (such as circulating tumor DNA, ctDNA in blood). These tests are used to identify gene mutations, copy number variations, gene fusions, abnormal expression, or epigenetic changes related to the occurrence, development, subtype, treatment response, and recurrence of cancer.

Profitability Analysis

Gross Profit Margin Levels

Genomic cancer testing is characterized by high technological barriers and high data interpretation value, though it remains highly dependent on laboratory automation, sample size, and payment coverage. Generally, the industry's gross profit margin is significantly higher than that of routine testing projects.

• Comprehensive Laboratory Companies: The gross profit margin for tumor gene testing business is commonly in the 50%-60% range.
• Leading Pure Molecular Diagnostics/Liquid Biopsy/High-end CGP Companies: These firms can typically reach margins of 60%-75%.

Key Drivers of Profitability:

• High Margin Factors: Product lines featuring high automation, strong data reuse capabilities, high report added value, and favorable medical/commercial insurance coverage.
• Margin Dilution Factors: Companies focusing on customized projects, low-throughput orders, complex manual interpretation, or regional sample delivery services face dilution due to channel, labor, and logistics costs.

Industry Benchmark: The average gross profit margin in this industry is generally higher than traditional pathology testing and significantly higher than most routine outsourced testing projects, though it remains lower than pure software SaaS.

Core Value Proposition: The industry's profitability is determined by platform-based testing capabilities, database capabilities, clinical evidence capabilities, and payment capabilities, rather than simply the revenue generated per sample tested.

Industry Drivers

The growth of the genomic cancer testing industry is driven by several key factors:

• Rising Cancer Burden: WHO/IARC data indicates nearly 20 million new cancer cases were diagnosed globally in 2022, a figure projected to reach 35 million by 2050. This increases demand for early screening, subtyping, targeted therapy selection, efficacy evaluation, and recurrence monitoring.
• Precision Medicine Penetration: The NCI has incorporated biomarker testing into treatment decision-making. Additionally, the increasing number of FDA-approved companion diagnostics means more anti-tumor drugs will rely on molecular testing for patient screening.
• Payment and Regulatory Improvements: The extension of CMS's NGS coverage policy and clear payment pricing for high-value CGP projects are transforming tumor gene testing from an "optional item" into a standard part of the medical process.
• Technological Advancements: Innovations in liquid biopsy, methylation detection, MRD, AI interpretation, and multi-omics joint analysis are improving detection sensitivity, lowering sampling thresholds, and extending testing from single diagnosis to full-course disease management.
• Pharmaceutical Industry Demand: Demand for companion diagnostics, biomarker discovery, patient stratification, and real-world evidence is driving the industry to evolve from single testing businesses into composite markets encompassing clinical services, drug development, and data asset operation.

Report Scope and Methodology

LPI (LP Information) Research Scope

The “Genomic Cancer Testing Industry Forecast” report by LPI provides:

• A review of total world Genomic Cancer Testing sales in 2025.
• A comprehensive analysis of projected sales for 2026 through 2032, broken down by region, market sector, and sub-sector (in US$ millions).
• Insights into product segmentation, company formation, revenue, market share, latest developments, and M&A activity.
• Analysis of leading global companies' portfolios, capabilities, market entry strategies, market positions, and geographic footprints.

Methodology

This study utilizes a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs to provide a nuanced view of the current state and future trajectory of the global market.

Market Segmentation

By Type

• Next-Generation Sequencing (NGS) Testing Products
• Digital PCR (dPCR) Testing Products
• Others

By Sample Type

• Tissue Sample Testing
• Blood Biopsy
• Others

By Cancer Type Coverage

• Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
• Genome Testing Products Specifically For Single Cancer Types
• Others

By Application

• Healthcare Institutions
• Biopharmaceuticals and Pharmaceuticals
• Independent Medical Laboratories
• Others

Geographic Segmentation

Americas

• United States
• Canada
• Mexico
• Brazil

APAC

• China
• Japan
• Korea
• Southeast Asia
• India
• Australia

Europe

• Germany
• France
• UK
• Italy
• Russia

Middle East & Africa

• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Key companies profiled are selected based on primary expert input and analysis of their coverage, product portfolio, and market penetration:

• Guardant Health (USA)
• Foundation Medicine (USA)
• Caris Life Sciences (USA)
• Tempus AI (USA)
• NeoGenomics (USA)
• Natera (USA)
• OncoDNA (Belgium)
• Agendia (Netherlands)
• Eurofins Clinical Diagnostics (Luxembourg)
• Unilabs Genetics (Switzerland)
• Nucleix (Israel)
• Genetron Health (China)
• Macrogen (South Korea)
• Geneseeq (China)
• 3DMed (China)
• BGI Genomics (China)
• Canhelp Genomics (China)
• Lucence (Singapore)
• MiRXES (Singapore)
• ACT Genomics (Taiwan)
• MedGenome (India)
• Strand Life Sciences (India)
• Sonic Genetics (Australia)
• NeoGenomics (USA)
• Labcorp Oncology (USA)

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Genomic Cancer Testing Market Size (2021-2032)

    • 2.1.2 Genomic Cancer Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Genomic Cancer Testing by Country/Region (2021, 2025 & 2032)

  • 2.2 Genomic Cancer Testing Segment by Type

    • 2.2.1 Next-Generation Sequencing (NGS) Testing Products

    • 2.2.2 Digital PCR (dPCR) Testing Products

    • 2.2.3 Others

    • 2.2.4 Genomic Cancer Testing Market Size by Type

      • 2.2.4.1 Genomic Cancer Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.4.2 Global Genomic Cancer Testing Market Size Market Share by Type (2021-2026)

  • 2.3 Genomic Cancer Testing Segment by Sample Type

    • 2.3.1 Tissue Sample Testing

    • 2.3.2 Blood Biopsy

    • 2.3.3 Others

    • 2.3.4 Genomic Cancer Testing Market Size by Sample Type

      • 2.3.4.1 Genomic Cancer Testing Market Size CAGR by Sample Type (2021 VS 2025 VS 2032)
      • 2.3.4.2 Global Genomic Cancer Testing Market Size Market Share by Sample Type (2021-2026)

  • 2.4 Genomic Cancer Testing Segment by Cancer Type Coverage

    • 2.4.1 Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors

    • 2.4.2 Genome Testing Products Specifically For Single Cancer Types

    • 2.4.3 Others

    • 2.4.4 Genomic Cancer Testing Market Size by Cancer Type Coverage

      • 2.4.4.1 Genomic Cancer Testing Market Size CAGR by Cancer Type Coverage (2021 VS 2025 VS 2032)
      • 2.4.4.2 Global Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage (2021-2026)

  • 2.5 Genomic Cancer Testing Segment by Application

    • 2.5.1 Healthcare Institutions

    • 2.5.2 Biopharmaceuticals and Pharmaceuticals

    • 2.5.3 Independent Medical Laboratories

    • 2.5.4 Others

    • 2.5.5 Genomic Cancer Testing Market Size by Application

      • 2.5.5.1 Genomic Cancer Testing Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.5.5.2 Global Genomic Cancer Testing Market Size Market Share by Application (2021-2026)

• 3 Genomic Cancer Testing Market Size by Player

  • 3.1 Genomic Cancer Testing Market Size Market Share by Player

    • 3.1.1 Global Genomic Cancer Testing Revenue by Player (2021-2026)

    • 3.1.2 Global Genomic Cancer Testing Revenue Market Share by Player (2021-2026)

  • 3.2 Global Genomic Cancer Testing Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Genomic Cancer Testing by Region

  • 4.1 Genomic Cancer Testing Market Size by Region (2021-2026)

  • 4.2 Global Genomic Cancer Testing Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Genomic Cancer Testing Market Size Growth (2021-2026)

  • 4.4 APAC Genomic Cancer Testing Market Size Growth (2021-2026)

  • 4.5 Europe Genomic Cancer Testing Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Genomic Cancer Testing Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Genomic Cancer Testing Market Size by Country (2021-2026)

  • 5.2 Americas Genomic Cancer Testing Market Size by Type (2021-2026)

  • 5.3 Americas Genomic Cancer Testing Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Genomic Cancer Testing Market Size by Region (2021-2026)

  • 6.2 APAC Genomic Cancer Testing Market Size by Type (2021-2026)

  • 6.3 APAC Genomic Cancer Testing Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Genomic Cancer Testing Market Size by Country (2021-2026)

  • 7.2 Europe Genomic Cancer Testing Market Size by Type (2021-2026)

  • 7.3 Europe Genomic Cancer Testing Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Genomic Cancer Testing by Region (2021-2026)

  • 8.2 Middle East & Africa Genomic Cancer Testing Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Genomic Cancer Testing Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Genomic Cancer Testing Market Forecast

  • 10.1 Global Genomic Cancer Testing Forecast by Region (2027-2032)

    • 10.1.1 Global Genomic Cancer Testing Forecast by Region (2027-2032)

    • 10.1.2 Americas Genomic Cancer Testing Forecast

    • 10.1.3 APAC Genomic Cancer Testing Forecast

    • 10.1.4 Europe Genomic Cancer Testing Forecast

    • 10.1.5 Middle East & Africa Genomic Cancer Testing Forecast

  • 10.2 Americas Genomic Cancer Testing Forecast by Country (2027-2032)

    • 10.2.1 United States Market Genomic Cancer Testing Forecast

    • 10.2.2 Canada Market Genomic Cancer Testing Forecast

    • 10.2.3 Mexico Market Genomic Cancer Testing Forecast

    • 10.2.4 Brazil Market Genomic Cancer Testing Forecast

  • 10.3 APAC Genomic Cancer Testing Forecast by Region (2027-2032)

    • 10.3.1 China Genomic Cancer Testing Market Forecast

    • 10.3.2 Japan Market Genomic Cancer Testing Forecast

    • 10.3.3 Korea Market Genomic Cancer Testing Forecast

    • 10.3.4 Southeast Asia Market Genomic Cancer Testing Forecast

    • 10.3.5 India Market Genomic Cancer Testing Forecast

    • 10.3.6 Australia Market Genomic Cancer Testing Forecast

  • 10.4 Europe Genomic Cancer Testing Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Genomic Cancer Testing Forecast

    • 10.4.2 France Market Genomic Cancer Testing Forecast

    • 10.4.3 UK Market Genomic Cancer Testing Forecast

    • 10.4.4 Italy Market Genomic Cancer Testing Forecast

    • 10.4.5 Russia Market Genomic Cancer Testing Forecast

  • 10.5 Middle East & Africa Genomic Cancer Testing Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Genomic Cancer Testing Forecast

    • 10.5.2 South Africa Market Genomic Cancer Testing Forecast

    • 10.5.3 Israel Market Genomic Cancer Testing Forecast

    • 10.5.4 Turkey Market Genomic Cancer Testing Forecast

  • 10.6 Global Genomic Cancer Testing Forecast by Type (2027-2032)

  • 10.7 Global Genomic Cancer Testing Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Genomic Cancer Testing Forecast

• 11 Key Players Analysis

  • 11.1 Guardant Health (USA)

    • 11.1.1 Guardant Health (USA) Company Information

    • 11.1.2 Guardant Health (USA) Genomic Cancer Testing Product Offered

    • 11.1.3 Guardant Health (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Guardant Health (USA) Main Business Overview

    • 11.1.5 Guardant Health (USA) Latest Developments

  • 11.2 Foundation Medicine (USA)

    • 11.2.1 Foundation Medicine (USA) Company Information

    • 11.2.2 Foundation Medicine (USA) Genomic Cancer Testing Product Offered

    • 11.2.3 Foundation Medicine (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Foundation Medicine (USA) Main Business Overview

    • 11.2.5 Foundation Medicine (USA) Latest Developments

  • 11.3 Caris Life Sciences (USA)

    • 11.3.1 Caris Life Sciences (USA) Company Information

    • 11.3.2 Caris Life Sciences (USA) Genomic Cancer Testing Product Offered

    • 11.3.3 Caris Life Sciences (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Caris Life Sciences (USA) Main Business Overview

    • 11.3.5 Caris Life Sciences (USA) Latest Developments

  • 11.4 Tempus AI (USA)

    • 11.4.1 Tempus AI (USA) Company Information

    • 11.4.2 Tempus AI (USA) Genomic Cancer Testing Product Offered

    • 11.4.3 Tempus AI (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Tempus AI (USA) Main Business Overview

    • 11.4.5 Tempus AI (USA) Latest Developments

  • 11.5 NeoGenomics (USA)

    • 11.5.1 NeoGenomics (USA) Company Information

    • 11.5.2 NeoGenomics (USA) Genomic Cancer Testing Product Offered

    • 11.5.3 NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 NeoGenomics (USA) Main Business Overview

    • 11.5.5 NeoGenomics (USA) Latest Developments

  • 11.6 Natera (USA)

    • 11.6.1 Natera (USA) Company Information

    • 11.6.2 Natera (USA) Genomic Cancer Testing Product Offered

    • 11.6.3 Natera (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Natera (USA) Main Business Overview

    • 11.6.5 Natera (USA) Latest Developments

  • 11.7 OncoDNA (Belgium)

    • 11.7.1 OncoDNA (Belgium) Company Information

    • 11.7.2 OncoDNA (Belgium) Genomic Cancer Testing Product Offered

    • 11.7.3 OncoDNA (Belgium) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 OncoDNA (Belgium) Main Business Overview

    • 11.7.5 OncoDNA (Belgium) Latest Developments

  • 11.8 Agendia (Netherlands)

    • 11.8.1 Agendia (Netherlands) Company Information

    • 11.8.2 Agendia (Netherlands) Genomic Cancer Testing Product Offered

    • 11.8.3 Agendia (Netherlands) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 Agendia (Netherlands) Main Business Overview

    • 11.8.5 Agendia (Netherlands) Latest Developments

  • 11.9 Eurofins Clinical Diagnostics (Luxembourg)

    • 11.9.1 Eurofins Clinical Diagnostics (Luxembourg) Company Information

    • 11.9.2 Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Product Offered

    • 11.9.3 Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Eurofins Clinical Diagnostics (Luxembourg) Main Business Overview

    • 11.9.5 Eurofins Clinical Diagnostics (Luxembourg) Latest Developments

  • 11.10 Unilabs Genetics (Switzerland)

    • 11.10.1 Unilabs Genetics (Switzerland) Company Information

    • 11.10.2 Unilabs Genetics (Switzerland) Genomic Cancer Testing Product Offered

    • 11.10.3 Unilabs Genetics (Switzerland) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Unilabs Genetics (Switzerland) Main Business Overview

    • 11.10.5 Unilabs Genetics (Switzerland) Latest Developments

  • 11.11 Nucleix (Israel)

    • 11.11.1 Nucleix (Israel) Company Information

    • 11.11.2 Nucleix (Israel) Genomic Cancer Testing Product Offered

    • 11.11.3 Nucleix (Israel) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Nucleix (Israel) Main Business Overview

    • 11.11.5 Nucleix (Israel) Latest Developments

  • 11.12 Genetron Health (China)

    • 11.12.1 Genetron Health (China) Company Information

    • 11.12.2 Genetron Health (China) Genomic Cancer Testing Product Offered

    • 11.12.3 Genetron Health (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 Genetron Health (China) Main Business Overview

    • 11.12.5 Genetron Health (China) Latest Developments

  • 11.13 Macrogen (South Korea)

    • 11.13.1 Macrogen (South Korea) Company Information

    • 11.13.2 Macrogen (South Korea) Genomic Cancer Testing Product Offered

    • 11.13.3 Macrogen (South Korea) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 Macrogen (South Korea) Main Business Overview

    • 11.13.5 Macrogen (South Korea) Latest Developments

  • 11.14 Geneseeq (China)

    • 11.14.1 Geneseeq (China) Company Information

    • 11.14.2 Geneseeq (China) Genomic Cancer Testing Product Offered

    • 11.14.3 Geneseeq (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.14.4 Geneseeq (China) Main Business Overview

    • 11.14.5 Geneseeq (China) Latest Developments

  • 11.15 3DMed (China)

    • 11.15.1 3DMed (China) Company Information

    • 11.15.2 3DMed (China) Genomic Cancer Testing Product Offered

    • 11.15.3 3DMed (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.15.4 3DMed (China) Main Business Overview

    • 11.15.5 3DMed (China) Latest Developments

  • 11.16 BGI Genomics (China)

    • 11.16.1 BGI Genomics (China) Company Information

    • 11.16.2 BGI Genomics (China) Genomic Cancer Testing Product Offered

    • 11.16.3 BGI Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.16.4 BGI Genomics (China) Main Business Overview

    • 11.16.5 BGI Genomics (China) Latest Developments

  • 11.17 Canhelp Genomics (China)

    • 11.17.1 Canhelp Genomics (China) Company Information

    • 11.17.2 Canhelp Genomics (China) Genomic Cancer Testing Product Offered

    • 11.17.3 Canhelp Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.17.4 Canhelp Genomics (China) Main Business Overview

    • 11.17.5 Canhelp Genomics (China) Latest Developments

  • 11.18 Lucence (Singapore)

    • 11.18.1 Lucence (Singapore) Company Information

    • 11.18.2 Lucence (Singapore) Genomic Cancer Testing Product Offered

    • 11.18.3 Lucence (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.18.4 Lucence (Singapore) Main Business Overview

    • 11.18.5 Lucence (Singapore) Latest Developments

  • 11.19 MiRXES (Singapore)

    • 11.19.1 MiRXES (Singapore) Company Information

    • 11.19.2 MiRXES (Singapore) Genomic Cancer Testing Product Offered

    • 11.19.3 MiRXES (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.19.4 MiRXES (Singapore) Main Business Overview

    • 11.19.5 MiRXES (Singapore) Latest Developments

  • 11.20 ACT Genomics (Taiwan)

    • 11.20.1 ACT Genomics (Taiwan) Company Information

    • 11.20.2 ACT Genomics (Taiwan) Genomic Cancer Testing Product Offered

    • 11.20.3 ACT Genomics (Taiwan) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.20.4 ACT Genomics (Taiwan) Main Business Overview

    • 11.20.5 ACT Genomics (Taiwan) Latest Developments

  • 11.21 MedGenome (India)

    • 11.21.1 MedGenome (India) Company Information

    • 11.21.2 MedGenome (India) Genomic Cancer Testing Product Offered

    • 11.21.3 MedGenome (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.21.4 MedGenome (India) Main Business Overview

    • 11.21.5 MedGenome (India) Latest Developments

  • 11.22 Strand Life Sciences (India)

    • 11.22.1 Strand Life Sciences (India) Company Information

    • 11.22.2 Strand Life Sciences (India) Genomic Cancer Testing Product Offered

    • 11.22.3 Strand Life Sciences (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.22.4 Strand Life Sciences (India) Main Business Overview

    • 11.22.5 Strand Life Sciences (India) Latest Developments

  • 11.23 Sonic Genetics (Australia)

    • 11.23.1 Sonic Genetics (Australia) Company Information

    • 11.23.2 Sonic Genetics (Australia) Genomic Cancer Testing Product Offered

    • 11.23.3 Sonic Genetics (Australia) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.23.4 Sonic Genetics (Australia) Main Business Overview

    • 11.23.5 Sonic Genetics (Australia) Latest Developments

  • 11.24 NeoGenomics (USA)

    • 11.24.1 NeoGenomics (USA) Company Information

    • 11.24.2 NeoGenomics (USA) Genomic Cancer Testing Product Offered

    • 11.24.3 NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.24.4 NeoGenomics (USA) Main Business Overview

    • 11.24.5 NeoGenomics (USA) Latest Developments

  • 11.25 Labcorp Oncology (USA)

    • 11.25.1 Labcorp Oncology (USA) Company Information

    • 11.25.2 Labcorp Oncology (USA) Genomic Cancer Testing Product Offered

    • 11.25.3 Labcorp Oncology (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)

    • 11.25.4 Labcorp Oncology (USA) Main Business Overview

    • 11.25.5 Labcorp Oncology (USA) Latest Developments

• 12 Research Findings and Conclusion